"Innovative drugs" of large pharmaceutical enterprises and small pharmaceutical enterprises listed in succession can also "reverse the wind"

On November 13, the drug evaluation center (CDE) of the State Food and Drug Administration (SFDA) completed the technical evaluation of the application for registration of Baiji Shenzhou PD-1 tirizumab, and the conclusion of the technical evaluation of the varieties was "production approval" In other words, it's only a step away from the official approval of the baiji Shenzhou PD-1 monoclonal antibody for Lei Lizhu On the evening of November 2, the National Drug Administration approved the launch of ganlute sodium capsule (gv-971), an original new drug for the treatment of Alzheimer's disease (AD), with the trade name of "phase 9, phase 1" China's innovative medicine has emerged from scratch, and we see that its pace of development is becoming faster and faster It's not a simple acceleration It's a race against life When the two terms "innovation" and "medicine" are combined, we will find that innovation has the thickness of life in this field, because it is about love, more about hope It is precisely because of the social demand for innovative drugs that the state is forced to speed up the examination and approval of new drugs, which in turn improves the R & D power and R & D power of enterprises As a big pharmaceutical country, the rise of China's pharmaceutical industry has never been achieved overnight, from weak to strong, from immature to mature, and each stage has encountered opportunities and challenges for development Now, "innovative drugs" has become a very important growth engine for pharmaceutical companies and the Chinese pharmaceutical market The most important point in the development of Chinese pharmaceutical industry is the relevant policy change As sun piaoyan, chairman of Hengrui, mentioned in the CCTV2 dialogue program: "the approval time is greatly shortened, so that we can put the product on the market as soon as possible, meet the expectations of many patients, and the drug market as soon as possible, and promote a virtuous cycle, so we will be more active to do so More new drugs to meet the needs of more patients So the policy innovation medicine for our country is the arrival of a spring " Indeed, from the perspective of policy, the speed of new drug approval has been accelerated For pharmaceutical enterprises, the time cost has been reduced and the innovation ability of pharmaceutical enterprises has been greatly improved From January 1, 2013 to now, there have been more than 1400 clinical trials of anti-tumor drugs on the clinical experiment Registration Platform of the State Food and drug administration, involving the common people in China with high incidence of tumors In the future, China's local biomedical companies will continue to take advantage of the arrival of the prime time of our biomedical industry to continue to develop and progress, and China's new anti-tumor drugs will continue to enter the clinical practice, obtain the approval of the competent department of the government, so that the era gives the soil of drug innovation, and bring new choices to the treatment of the people On the other hand, if policy is the first prerequisite for the development of innovative drugs, then talent and capital are the remaining two of the development of innovative drugs The 10-year cost of carrelizumab from Hengrui is 20 yuan, and the 7-year cost of Cinda bio sindelimab is 1.5 billion yuan, which can be said to be extremely expensive Therefore, the birth of every innovative drug requires strong financial support Of course, the same is true of talents Yu Dechao, chairman of Cinda biology, once shared that in South San Francisco, it is called the birthplace of biomedicine in the world The reason is that the world's first biomedical company was born here, and the most important contribution is the continuous high-quality talents from Stanford University and the University of California So the most important thing is to innovate Or talent.